Kim Steegen
Overview
Explore the profile of Kim Steegen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
511
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Byun H, Papathanasopoulos M, Steegen K, Basson A
Viruses
. 2025 Jan;
16(12.
PMID: 39772195
Islatravir (ISL) is the first-in-class nucleoside reverse transcriptase translocation inhibitor (NRTtI) with novel modes of action. Data on ISL resistance are currently limited, particularly to HIV-1 non-B subtypes. This study...
2.
Reddy N, Papathanasopoulos M, Steegen K, Basson A
Viruses
. 2024 Sep;
16(9).
PMID: 39339969
Doravirine (DOR) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) with efficacy against some NNRTI-resistant mutants. Although DOR resistance mutations are established for HIV-1 subtype B, it is less clear for...
3.
Kanise H, van Oosterhout J, Bisani P, Songo J, Matola B, Chipungu C, et al.
Viruses
. 2024 Jan;
16(1).
PMID: 38257730
Millions of Africans are on dolutegravir-based antiretroviral therapy (ART), but few detailed descriptions of dolutegravir resistance and its clinical management exist. We reviewed HIV drug resistance (HIVDR) testing application forms...
4.
Inzaule S, Siedner M, Little S, Avila-Rios S, Ayitewala A, Bosch R, et al.
PLoS Med
. 2023 Sep;
20(9):e1004293.
PMID: 37738247
• Human immunodeficiency virus (HIV) drug resistance has implications for antiretroviral treatment strategies and for containing the HIV pandemic because the development of HIV drug resistance leads to the requirement...
5.
Steegen K, van Zyl G, Claassen M, Khan A, Pillay M, Govender S, et al.
Diagnostics (Basel)
. 2023 Jul;
13(13).
PMID: 37443603
Monitoring of HIV drug resistance (HIVDR) remains critical for ensuring countries attain and sustain the global goals for ending HIV as a public health threat by 2030. On an individual...
6.
Hunt G, Yousif M, Levin L, Ledwaba J, Steegen K, Kufa T, et al.
J Antimicrob Chemother
. 2023 Apr;
78(5):1160-1167.
PMID: 37017009
Background: Minimal data exist on HIV drug resistance patterns and prevalence among paediatric patients failing ART in resource-limited settings. We assessed levels of HIV drug resistance in children with virological...
7.
Munir R, Scott L, Noble L, Steegen K, Hans L, Stevens W
Microbiol Spectr
. 2023 Feb;
:e0371622.
PMID: 36853026
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in late 2019, and its rapid spread around the globe led the World Health Organization to declare it a pandemic. Laboratory diagnostics...
8.
Steegen K, Chandiwana N, Sokhela S, Venter W, Hans L
AIDS
. 2023 Feb;
37(6):1009-1011.
PMID: 36779485
Baseline rilpivirine drug resistance mutations (DRMs) are a risk factor for virological failure in patients treated with long-acting cabotegravir and rilpivirine (CAB/RPV LA). We investigated rilpivirine cross-resistance in treatment-naive and...
9.
Noble L, Scott L, Munir R, du Plessis M, Steegen K, Hans L, et al.
Diagnostics (Basel)
. 2023 Jan;
13(1).
PMID: 36611325
The Xpert Xpress SARS-CoV-2 and Xpert Xpress SARS-CoV-2/Flu/RSV tests were rapidly developed and widely used during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. In response to emerging genetic...
10.
Botha J, Steegen K, Edoo M, Nel J, van Zyl G
South Afr J HIV Med
. 2022 Oct;
23(1):1398.
PMID: 36299554
No abstract available.